AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
AXIM BIOTECHNOLOGIES, INC.
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2024
Total debt
$186.49K
$92.65K due within a year
Net debt
$180.45K
After $6.04K of cash
Implied interest rate
–
FY2023 interest ÷ average debt
Interest coverage
-19.6×
FY2023 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Axim Biotechnologies's annual report. Trading prices and yields need FINRA TRACE data.